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Background: The purpose of this study was to investigate the effect of estrogen alteration on the expression of
caveolin 2 and 3 in rat smooth muscle of urinary bladder.
Methods: Female Sprague–Dawley rats were divided into three groups: control, bilateral ovariectomy (Ovx), and
bilateral ovariectomy followed by subcutaneous injections of 17β-estradiol (Ovx + Est). After 4 weeks, urodynamic
measurements were taken to ascertain the contraction interval and contraction pressure. The expression and
cellular localization of caveolin 2 and 3 were determined by Western blot and immunohistochemistry in rat urinary
bladder smooth muscle.
Results: In cystometrograms, the contraction interval (min) was significantly lower in the Ovx group (3.1 ± 1.5) than
in the control group (5.6 ± 1.2), but was increased after estrogen treatment (9.3 ± 1.0). Conversely, the average
contraction pressure (mmHg) was higher in the Ovx group (26.2 ± 2.3) than in the control group (21.9 ± 3.1), and
was decreased after estrogen treatment (23.8 ± 3.5). Caveolin 2 and 3 expression was localized in the cell
membrane of the smooth muscle. The protein expression of both caveolin 2 and 3 was significantly lower after
ovariectomy and was restored to the control levels after 17β-estradiol treatment.
Conclusions: Hormonal alteration causes a significant change in the expression of caveolin 2 and 3 in smooth
muscle of rat urinary bladder. These findings suggest that these molecules might have functional roles in the
detrusor overactivity that occurs in association with hormonal alteration.
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Caveolae are small invaginations of the cell membrane
that are membrane attached vesicular organelles present
in most cell types, and which are particularly abundant
in smooth muscle cells [1]. Caveolae are thought to play
an important role in cell surface signaling and intracellu-
lar lipid transport [2]. Caveolins are major constituents
of caveolae. Among them, caveolin 2 is expressed in many
cell types, whereas caveolin 3 is the specific isoform that is
present in skeletal and smooth muscle cells [3]. A complex* Correspondence: urokwon@gmail.com
1Department of Urology, Research Institute of Medical Sciences, Chonnam
National University, 8, Hak-dong, Dong-ku, Gwangju 501-757, Korea
Full list of author information is available at the end of the article
© 2013 Kim et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand diverse functional role of caveolin has been proposed
to provide a protective platform that regulates various sig-
nal molecules and may facilitate and integrate the cellular
response to the specific extracellular stimulus [4,5]. Previ-
ously we investigated the effect of hormonal alterations on
the expression of caveolin 1 in the urinary bladders of
ovariectomized rats and reported that hormonal alter-
ations cause a significant change in the expression of
caveolin 1, which suggests that caveolin 1 might have a
functional role in the overactivity of the detrusor muscle
related to hormonal alterations in the urinary bladders [6].
Estrogen withdrawal induces a pronounce change in aged
rat urinary bladder smooth muscle and estrogen replace-
ment increases caveolar number and caveolinl protein [7].
Estrogen is essential for the physiologic function of the
female lower urinary tract, which is believed to play an im-
portant role in bladder function [8,9]. Menopause or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tract symptoms, and estrogen treatment for these subjects
can induce pronounced alterations in these symptoms
from the estrogen depletion [10,11]. No studies to date
have investigated the changes in expression of caveolin 2
and caveolin 3 in the bladder smooth muscle of ovariecto-
mized rats or the functional activity of these proteins in re-
sponse to hormonal alteration.
The present study investigated the impact of estrogen
on the expression of caveolin 2 and caveolin 3 of smooth
muscle in rat urinary bladder. The specific aims of the
present study were to examine how the protein expression
of caveolin 2 and caveolin 3 changed in estrogen-depleted
or replaced smooth muscle, and whether the altered density
of caveolins correlated with altered contractile response in
the rat urinary bladder smooth muscle. Understanding the
effect of caveolin 2 and 3 on bladder smooth muscle under
the hormonal change of estrogen could provide valuable
insight into the mechanism regulating bladder overactivity
and could identify caveolin protein as a promising target
for the treatment of bladder dysfunction or bladder over-




Female Sprague–Dawley rats (12 weeks old, 230–240 g,
N = 45) were divided into three groups: control (Con, N =
15), bilateral ovariectomy (Ovx, N = 15), and bilateral ovari-
ectomy plus subcutaneous injection with 17β-estradiol
(Sigma-Aldrich, St. Louis, MO, USA) (Ovx + Est, N = 15).
The Con group underwent a sham operation. The Ovx
group underwent a bilateral ovariectomy with intramuscu-
lar injection of zolazepam/tiletamine cocktail (4.4 mg/kg)
and was treated with a subcutaneous injection of an oil ve-
hicle. The Ovx + Est group underwent a bilateral ovariec-
tomy, followed by treatment with subcutaneous estradiol
daily (50 ug/kg/day) from 7 days after ovariectomy. All ex-
perimental animals were fed a standard diet up until the
day before the experiment. Four weeks after ovariectomy
and 3 weeks after hormonal replacement, animals with
an estrous cycle confirmed via a vaginal smear were anes-
thetized with an intramuscular injection of a zolazepam/
tiletamine cocktail (4.4 mg/kg) for tissue dissection after the
cystometry. The study was approved by the Ethics Commit-
tee of Chonnam National University Medical School.
Cystometrogram
Four weeks after the ovariectomy, 5 rats in each group
were anesthetized with 1.2 g/kg urethane injected subcuta-
neously. A suprapubic midline incision was performed to
expose the bladder, a transvesical catheter with a fire-flared
tip (polyethylene catheter-50) was inserted into the dome
of the bladder and secured with a ligature, and theabdomen was closed. The catheter was connected to a
pressure transducer and syringe pump via a 3-way stop-
cock to record intravesical pressure and to infuse saline
into the bladder. After the bladder was emptied,
cystometry was performed with saline infused at a rate
of 0.04 ml/min. The contraction pressure and contrac-
tion interval were recorded.
Immunofluorescence staining
The tissue sections (N = 5 in each group, eight sections
in each tissue) were rinsed in phosphate-buffered saline
(PBS), and then treated with 3% hydrogen peroxide in
60% methanol for 30 min to quench endogenous perox-
idase activity. After washing in PBS, tissue sections were
treated with normal chicken serum for 30 min to block
nonspecific binding. After being washed in PBS, the sec-
tions were incubated with a 1:50 dilution in PBS of anti-
body for caveolin 2 or caveolin 3 (Chemicon, Temecula,
CA, USA) for 12–14 h at 4°C. Immunoreactivity for
caveolin 2 and caveolin 3 were detected with the use of
Alexa-Fluor 594 chicken anti-mouse IgG (1;100, H + L;
Invitrogen, Carlsbad, CA, USA). Tissues were mounted
with the use of a mounting solution containing 4-6-
diamidino-2-phenylindole. For a negative control, tissues
were prepared in a similar manner, except that caveolin
2 and caveolin 3 were omitted from the incubation solution.
Tissues were examined with a model LSM 510 confocal
microscope (Carl Zeiss, Jena, Germany) with an excitation
wavelength appropriate for Alexa-Fluor (405 or 594 nm).
Final images were constructed with the use of LSM Image
Examiner software.
Western blot
All minced tissues were homogenized in ice-cold isola-
tion solution with a Tissumizer homogenizer (Tekmar,
Cincinnati, OH, USA). Tissues were homogenized with
five bursts of five strokes of a micro-sawtooth gener-
ator. Tissue homogenates (N = 5 in each group, 30 μg
of protein) were separated by 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred
to polyvinylidene fluoride membranes (Amersham Phar-
macia Biotech, England, UK). The blots were then washed
with Tris-Buffered Saline Tween (10 mM Tris–HCl, pH 7.6,
150 mM NaCl, 0.05% Tween-20). Each membrane was
blocked with 5% skimmed milk for 1 h and incubated with
the appropriate primary antibody. Monoclonal rabbit anti-
bodies for caveolin 2 and caveolin 3 (1;1500, Chemicon)
and polyclonal rabbit antibody against glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (1;4000, Cell Signaling
Technology, Danvers, MA, USA) were used. The mem-
brane was then washed, and caveolin-2, caveolin-3, and
GAPDH were detected with goat anti-mouse-IgG and goat
anti-rabbit-IgG conjugated to horseradish peroxidase, re-
spectively. Antibody incubations were performed in a
Figure 1 Representative urodynamic profiles of three groups of rats: a control group (Con), a group that underwent bilateral
ovariectomy (Ovx), and a group that underwent bilateral ovariectomy followed by subcutaneous injections of 17β-estradiol (Ovx +
Est). The contraction interval in the Ovx group was significantly shorter than that in the Con group (P < 0.05) and was restored to the control
value after estrogen treatment (P < 0.05). Note the increased peak pressures with each voiding contraction in the Ovx group and recovery to the
control value in the Ovx + Est group. The lower panels denote the means ± standard errors of the mean of 5 experiments for each condition
determined by cystometrogram. *P < 0.05 vs. control, **P < 0.05 vs. Ovx.
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chemiluminescence (Amersham Pharmacia Biotech,
Buckinghamshire, UK). GAPDH was used as an internal
control. Densitometry analysis was performed with a Stu-
dio Star Scanner using NIH image V1-57 software.Figure 2 Immunofluorescence labeling for caveolin2 and caveolin3 in r
throughout the cell membrane in the smooth muscle layers. Both caveolin 2
but returned to the control value after estrogen treatment, as demonstrated b
each figure indicates the magnification power. The right panels denote the m
densitometry. Con = control; Ovx = ovariectomy; Ovx + Est = ovariectomy plusStatistical analysis
The results are expressed as mean ± standard deviation,
except for the data for the cystometric parameters, which
are expressed as mean ± standard error of the mean. Ana-
lysis of variance was used to test the null hypothesis thatat urinary bladder. Caveolin2 and caveolin3 expression (red) was noted
and caveolin 3 showed decreased immunoreactivity in the Ovx group
y the Ovx + Est group. The horizontal scale bar at the bottom left of
eans ± SD of 5 experiments for each condition determined by relative
17β-estradiol treatment. *P < 0.05 vs. control, **P < 0.05 vs. Ovx.
Figure 3 Immunoblotting of caveolin2 and caveolin3 in the rat
urinary bladder. The anti-caveolin 2 and caveolin 3 antibodies
recognized 18–20 kDa bands. Anti-GAPDH antibody recognized the
42 kDa band. Caveolin 2 and caveolin 3 protein expressions were
significantly decreased in the Ovx group. However, this expression
was restored to the level of the control after 17β-estradiol treatment
in the Ovx + Est group. The lower panels denote the mean ±
standard deviation of 5 experiments for each condition determined
by densitometry relative to GAPDH. Con = control; Ovx =
ovariectomy; Ovx + Est = ovariectomy plus 17β-estradiol treatment;
*P < 0.05 vs. control; **P < 0.05 vs. Ovx.
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levels between the three groups. Differences were consid-
ered significant at P < 0.05.
Results
All animals survived for 4 weeks after surgery. Body weight
(g) was significantly higher in the Ovx group (362.3 ± 10.1)
than in the control group (267.1 ± 11.5)(P = 0.01). Treat-
ment of ovariectomized animals with 17β-estradiol re-
duced the body weight to the control level (285.6 ± 13.2)
(P = 0.03). There was no significant difference in bladder
weight between the groups.
Effect of estrogen on the cystometric parameters
In cystometrograms performed 4 weeks after the oper-
ation, the contraction interval (min) was significantly lo-
wer in the Ovx group (3.1 ± 1.5) than in the control
group (5.6 ± 1.2)(P = 0.02), but was increased after estro-
gen treatment (9.3 ± 1.0) (P = 0.01). Conversely, the aver-
age contraction pressure (mmHg) was higher in the Ovx
group (26.2 ± 2.3) than in the control group (21.9 ± 3.1)
(P = 0.03) and was decreased after estrogen treatment
(23.8 ± 3.5)(P = 0.04)(Figure 1).
Effect of estrogen on the expression of caveolin 2 and
caveolin 3
The expression of caveolin 2 and caveolin 3 was easily
detected in the smooth muscle of all groups. Caveolin 2
and caveolin 3 was mainly expressed in the cell mem-
brane of the smooth muscle. Immunofluorescence staining
showed that the Ovx group had a decreased expression
of caveolin 2 (P = 0.02) and caveolin 3 (P = 0.01) that
was restored to the control level after estrogen treat-
ment (Ovx + Est group; caveolin 2, P = 0.01; caveolin 3,
P = 0.01)(Figure 2).
Western blot analysis revealed bands at 20 kDa corre-
sponding to caveolin 2 and caveolin 3 proteins (Figure 3).
Caveolin 2 (P = 0.04) and caveolin 3 (P = 0.04) protein ex-
pression was significantly lower after ovariectomy. How-
ever, the expression of these proteins was restored to
the control level after 17β-estradiol treatment (caveolin 2,
P = 0.02; caveolin 3, P = 0.01) (Figure 3).
Discussion
In the present study, the expression of caveolin 2 and
caveolin 3 was significantly decreased in the ovariectomy
group but was restored to the control level after 17β-
estradiol treatment. These results suggest that hormonal
alteration may change the expression of caveolins in rat
urinary bladder and that caveolins may play a role in the
bladder dysfunction induced by ovariectomy and hormo-
nal change.
The urinary tract is sensitive to female sex steroids
and estrogen. Surgical removal of ovary and estrogenadministration induced pronounced alterations in lower
urinary tract structure and bladder function in an animal
study [12]. Ovariectomy can induce bladder change such
as decreased bladder compliance, and decreased detrusor
contractility [1]. It is believed that alterations in circulating
estrogen levels play a major role in mediating bladder
physiology and related subjective symptoms, including ur-
gency, frequency, and an overactive or underactive de-
trusor muscle. In real practice in the urologic clinic, most
postmenopausal women are subject to several urologic
dysfunctions, such as overactive bladder symptoms, in-
continence, and urinary tract infections [13].
Caveolae has been considered to mediate several im-
portant cellular processes such as regulation of lipid trans-
port, cholesterol homeostasis, endocytosis and transcytosis
[14,15]. Recently, diverse and complex roles of caveolae
have been proposed in smooth muscle cells; these roles
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would facilitate, organize, and integrate responses to extra-
cellular stimuli [5]. However, caveolins are major structural
components of caveolae by bind cholesterol and promote
the formation of an invaginated caveolae structure [16].
The caveolin protein family consists of three members:
caveolin 1, caveolin 2, and caveolin 3. All three have been
detected in smooth muscle cells.
A study conducted using caveolin 1 knockout mice
provided evidence implicating caveolin in urinary blad-
der activity; loss of caveolin 1 impaired urinary bladder
contraction and was associated with disruption of M3
muscarinic cholinergic activity in the bladder [17]. Sev-
eral studies have shown that caveolae regulate bladder
smooth muscle and modulate bladder contraction, and
have documented pronounced alteration in caveolae under
specific conditions [17-19]. Polyák et al. reported decreased
numbers of caveolae in hypertrophied detrusor smooth
muscle, which might contribute to alterations in signal
transduction pathways that regulate the downstream effects
of agonist induced bladder contraction [18]. Cristofaro
et al. examined the expression of caveolin1, 2, and 3 in rat
urinary bladder tissue and found reduced agonist induced
bladder contraction after cholesterol depletion that was re-
stored following cholesterol replacement [19]. The authors
opined that caveolins have a central role in the regulation
of receptor signaling pathways in bladder smooth muscle.
To date no study has investigated the changes in ex-
pression of caveolin 2 and 3 in bladder smooth muscle
or the functional activity of these proteins in response to
hormonal alteration. We already investigated the effect
of hormonal alterations on the expression of caveolin 1 in
the bladder smooth muscle which suggests that caveolin 1
might have a functional role in the detrusor overactivity
related to hormonal alterations [6]. In the present study,
the same alteration of the expression of caveolin 2 and
caveolin 3 as our previous report of caveolin 1 in the
smooth muscle of urinary bladder was found. It is sug-
gested that all the three isoforms of caveolin (caveolin 1, 2,
and 3) have a functional role in the overactivity of the de-
trusor muscle without being able to understand what is
most expressed in the detrusor muscle and which may
play the main functional role.
One of the possible reasons behind this influence on
caveolin expression is believed to be the significance of the
location of the molecules in the urinary bladder: the smooth
muscle of urinary bladder is highly dependent on hormonal
alterations, which induce functional change of the urinary
bladder smooth muscle after estrogen deprivation.
Our results suggest that ovariectomy may lead to sig-
nificant down-regulation of caveolin 2 and caveolin 3 ex-
pressions in rat urinary bladder, providing presumptive
evidence that caveolins are involved in the lower urinary
tract symptoms induced by hormonal alteration, probablyby modification of signal transmission via caveolae in the
smooth muscle. A limitation of our study is that the pre-
cise functional activity of caveolins was not fully unveiled,
although we did show the clear change in expression of
caveolins in the ovariectomy rat urinary bladder. Further
studies are needed to investigate role of the caveolins in
the underlying mechanisms of pathophysiology of bladder
dysfunction after hormonal change.
Conclusion
Hormonal alteration causes a significant change in the ex-
pression of caveolin 2 and 3 in smooth muscle of rat urin-
ary bladder. These findings suggest that these molecules
might have functional roles in the detrusor overactivity
that occurs in association with hormonal alteration.
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